Wednesday, July 08, 2020 5:20:31 AM
First time looking at this stick so excuse me if I got it wrong, but please explain
Is it just me or anyone else questioning the TAEUS' ability to accurately quantify liver fat. Read the clinical trial posted on their website. Seems to me that they are missing about 20% of patients with liver fat >6%. How does that work in real life. Wouldn't we simply just continue using biopsy and be sure ?
Is it just me or anyone else questioning the TAEUS' ability to accurately quantify liver fat. Read the clinical trial posted on their website. Seems to me that they are missing about 20% of patients with liver fat >6%. How does that work in real life. Wouldn't we simply just continue using biopsy and be sure ?
Recent NDRA News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/21/2026 12:00:21 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2026 09:10:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 08:29:26 PM
- ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update • Business Wire • 03/31/2026 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 01:21:26 PM
- ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value • Business Wire • 03/25/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 02:48:01 AM
- ENDRA’s TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care • Business Wire • 02/26/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2026 12:43:37 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2026 12:43:22 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2026 12:43:04 AM
- ENDRA’s TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use • Business Wire • 12/04/2025 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/28/2025 09:23:04 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 11/26/2025 01:30:32 PM
- ENDRA Feasibility Study Demonstrates TAEUS® Accurately Quantifies Liver Fat Fraction, a Key MASLD/MASH Biomarker • Business Wire • 11/20/2025 01:00:00 PM
- ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results • Business Wire • 11/17/2025 01:00:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/14/2025 09:38:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 09:27:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:24:12 PM
- ENDRA Life Sciences Commences Staking of HYPE Digital Asset Holdings, Reinforcing Long-Term Strategy with Anchorage Digital and ARCA • Business Wire • 11/13/2025 01:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/06/2025 10:00:59 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 10/28/2025 10:43:58 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 10/28/2025 11:10:18 AM
